Compare Stocks

Date Range: 

 Purple BiotechMonopar TherapeuticsAzurRx BioPharmaAgeX TherapeuticsPulmatrix
SymbolNASDAQ:PPBTNASDAQ:MNPRNASDAQ:AZRXNYSE:AGENASDAQ:PULM
Price Information
Current Price$3.97$5.28$0.82$1.31$0.89
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score0.61.51.40.51.3
Analysis Score0.03.53.40.03.5
Community Score2.53.13.02.42.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.00.0
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ABuy
Consensus Price Target$25.00$30.00$3.50N/A$5.00
% Upside from Price Target529.72% upside468.18% upside326.88% upsideN/A459.35% upside
Trade Information
Market Cap$69.52 million$66.37 million$61.03 million$49.70 million$50.28 million
Beta2.33N/A1.811.51.66
Average Volume739,838220,3367,917,188309,0502,241,172
Sales & Book Value
Annual Revenue$1 millionN/AN/A$1.73 million$7.91 million
Price / Sales69.52N/AN/A28.736.36
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.56 per share$1.19 per share$0.17 per share$0.07 per share$0.55 per share
Price / Book0.71N/AN/A18.711.63
Profitability
Net Income$-5,850,000.00$-4,220,000.00$-15,180,000.00$-12,150,000.00$-20,600,000.00
EPS($3.00)($0.45)N/AN/A($0.80)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-582.11%-166.00%
Return on Equity (ROE)N/A-42.84%-316.41%-932.89%-147.81%
Return on Assets (ROA)N/A-40.98%-162.80%-207.13%-56.43%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio2.22%29.65%4.40%0.40%3.51%
Quick RatioN/A29.65%4.40%0.40%3.51%
Ownership Information
Institutional Ownership Percentage2.68%0.66%5.14%13.17%19.33%
Insider Ownership Percentage2.98%48.40%7.30%3.33%4.25%
Miscellaneous
Employees13912620
Shares Outstanding17.51 million12.57 million74.44 million37.94 million56.25 million
Next Earnings DateN/AN/A5/21/2021 (Estimated)5/13/2021 (Estimated)5/13/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50-Day Moving Average of $1.18Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50-Day Moving Average of $1.18
americanbankingnews.com - May 8 at 3:42 AM
After A -26.22% Fall This Year Is Pulmatrix Inc. (NASDAQ:PULM) A Better Buy Than Others?After A -26.22% Fall This Year Is Pulmatrix Inc. (NASDAQ:PULM) A Better Buy Than Others?
marketingsentinel.com - May 7 at 9:22 AM
Returns At Performance Shipping (NASDAQ:PSHG) Are On The Way Up - NasdaqReturns At Performance Shipping (NASDAQ:PSHG) Are On The Way Up - Nasdaq
nasdaq.com - May 3 at 11:07 PM
Heres Why Were Not Too Worried About Pulmatrixs (NASDAQ:PULM) Cash Burn Situation - NasdaqHere's Why We're Not Too Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Situation - Nasdaq
nasdaq.com - May 3 at 5:54 PM
Is There A Reason Why Pulmatrix (PULM) Stock Rose In After-Hour Trading? - Market GlobalistIs There A Reason Why Pulmatrix (PULM) Stock Rose In After-Hour Trading? - Market Globalist
marketglobalist.com - May 3 at 7:53 AM
Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 37.9% in AprilPulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 37.9% in April
americanbankingnews.com - April 30 at 10:56 AM
 Analysts Expect Pulmatrix, Inc. (NASDAQ:PULM) Will Announce Earnings of -$0.10 Per Share Analysts Expect Pulmatrix, Inc. (NASDAQ:PULM) Will Announce Earnings of -$0.10 Per Share
americanbankingnews.com - April 28 at 2:27 PM
Pulmatrix, Inc. (NASDAQ:PULM)’s Stock Price Continues to FallPulmatrix, Inc. (NASDAQ:PULM)’s Stock Price Continues to Fall
stocksregister.com - April 27 at 2:30 PM
Pulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned - COPD News TodayPulmatrix Regains Rights to PUR1800 for COPD, Phase 2 Trial Planned - COPD News Today
copdnewstoday.com - April 19 at 12:29 PM
Pulmatrix (NASDAQ:PULM) Price Target Cut to $5.00 by Analysts at HC WainwrightPulmatrix (NASDAQ:PULM) Price Target Cut to $5.00 by Analysts at HC Wainwright
americanbankingnews.com - April 19 at 11:32 AM
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine - Woburn Daily TimesPulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine - Woburn Daily Times
homenewshere.com - April 15 at 6:26 PM
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine - Yahoo FinancePulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine - Yahoo Finance
finance.yahoo.com - April 15 at 1:26 PM
The Petri Dish: Oncology startup debuts, J&J kills Pulmatrix licensing deal - Boston Business Journal - Boston Business JournalThe Petri Dish: Oncology startup debuts, J&J kills Pulmatrix licensing deal - Boston Business Journal - Boston Business Journal
bizjournals.com - April 15 at 1:26 PM
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute MigrainePulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine
finance.yahoo.com - April 15 at 1:26 PM
Pulmatrix (PULM) Stock Moves Back Below $1 Mark: A Good Buy? – Own Snap - Own SnapPulmatrix (PULM) Stock Moves Back Below $1 Mark: A Good Buy? – Own Snap - Own Snap
ownsnap.com - April 14 at 10:37 AM
Is Pulmatrix Inc (PULM) Stock at the Top of the Biotechnology Industry? - InvestorsObserverIs Pulmatrix Inc (PULM) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - April 14 at 12:36 AM
Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%
nasdaq.com - April 13 at 2:34 PM
BRIEF-Pulmatrix Inc Plans To Initiate Pur1800 Phase 2B Proof-Of-Concept Efficacy Study For Treatment Of Aecop In 2022BRIEF-Pulmatrix Inc Plans To Initiate Pur1800 Phase 2B Proof-Of-Concept Efficacy Study For Treatment Of Aecop In 2022
msn.com - April 13 at 9:32 AM
Pulmatrix: J&J Terminates License, Development, Commercialization PactPulmatrix: J&J Terminates License, Development, Commercialization Pact
morningstar.com - April 13 at 9:32 AM
HC Wainwright Lowers Pulmatrix (NASDAQ:PULM) Price Target to $5.00HC Wainwright Lowers Pulmatrix (NASDAQ:PULM) Price Target to $5.00
americanbankingnews.com - April 13 at 8:34 AM
Other news to note for April 12, 2021 | 2021-04-12 - BioWorld OnlineOther news to note for April 12, 2021 | 2021-04-12 - BioWorld Online
bioworld.com - April 13 at 4:31 AM
Form 8-K Pulmatrix, Inc. For: Apr 06 - StreetInsider.comForm 8-K Pulmatrix, Inc. For: Apr 06 - StreetInsider.com
streetinsider.com - April 13 at 4:31 AM
Pulmatrix (PULM) to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio - StreetInsider.comPulmatrix (PULM) to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio - StreetInsider.com
streetinsider.com - April 13 at 4:31 AM
Pulmatrix slips 15% after J&J terminates license agreement - Seeking AlphaPulmatrix slips 15% after J&J terminates license agreement - Seeking Alpha
seekingalpha.com - April 13 at 4:31 AM
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio - Woburn Daily TimesPulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio - Woburn Daily Times
homenewshere.com - April 13 at 4:31 AM
DateCompanyBrokerageAction
12/31/2020Purple BiotechHC WainwrightReiterated Rating
1/28/2021Monopar TherapeuticsRoth CapitalInitiated Coverage
9/24/2020Monopar TherapeuticsMaxim GroupInitiated Coverage
2/19/2020Monopar TherapeuticsBrookline Capital ManagementInitiated Coverage
1/6/2021AzurRx BioPharmaDawson JamesDowngrade
6/11/2019AzurRx BioPharmaNational SecuritiesInitiated Coverage
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.